Form 4: Protagonist CEO Sells Shares for Tax Obligations

Protagonist Therapeutics' President and CEO, Dinesh V. Patel, sold 34,438 shares of common stock at $82.48 per share to cover tax withholding obligations.

Summary

• Dinesh V. Patel, President and CEO, and a Director of Protagonist Therapeutics, Inc. (PTGX), reported a sale of common stock.
• On January 20, 2026, Patel sold 34,438 shares of Protagonist Therapeutics common stock.
• The shares were sold at a price of $82.48 per share.
• The transaction was executed to cover tax withholding obligations incurred upon the settlement of restricted stock units.
• Following this transaction, Patel directly beneficially owns 580,505 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations from restricted stock unit settlement, which is a neutral event for the company's fundamentals and stock price.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned, non-discretionary sale.
• The sale was specifically for covering tax withholding obligations, which is a routine and expected event for executive compensation involving restricted stock units.

Negatives

• A reduction in direct beneficial ownership by 34,438 shares, although for a specific, non-discretionary reason.

Risks

• No specific new risks are introduced by this routine tax-related sale.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

This routine insider transaction for tax purposes does not provide specific insights into broader industry trends or competitive landscape. It is a standard event related to executive compensation in publicly traded companies, common across various sectors including biotechnology.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the CEO's direct beneficial ownership, but it is for a routine tax purpose and not indicative of a change in confidence.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• No specific future actions, events, or milestones were mentioned in this Form 4 filing.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale of shares by the CEO to cover tax withholding obligations associated with the settlement of restricted stock units. This is a common occurrence for executives receiving equity compensation and does not reflect a change in the company's fundamental outlook or the CEO's confidence in the company. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Protagonist Therapeutics, PTGX, Dinesh V. Patel, Insider Sale, Form 4, Tax Withholding, Restricted Stock Units, CEO, Director, Biotechnology